An FDA advisory panel has voted to expand access to four peptides, amid growing interest in these unapproved therapies. Peptides, which are short chains of amino acids, are naturally produced by the body and used in various approved medications. However, the demand for unapproved peptides, often marketed online for benefits like anti-aging and muscle growth, has surged despite lacking scientific backing. During a two-day meeting, the panel reviewed seven peptides, voting 8-6 to allow compounding pharmacies to produce four of them, including BPC-157, TB-500, MOTS-c, and KPV, with a doctor’s prescription for specific medical conditions. This decision does not equate to FDA approval but may lead to increased marketing by telehealth companies. The panel’s discussions highlighted differing opinions, with some experts cautioning against the lack of evidence and others advocating for broader access based on personal experiences.
QUESTION: How might the increased availability of unapproved peptides impact public health and consumer safety?
FDA panel recommends loosening regulations for some peptides
